94 results on '"Menacho M"'
Search Results
2. P020 Effects of Anti-TNF Treatment on Browning of Mesenteric Adipose Tissue with Crohn's Disease
- Author
-
Montfort-Ferré, D, primary, Vaño-Segarra, I, additional, Boronat-Toscano, A, additional, Menacho, M, additional, Moliné, A, additional, Cepero, C, additional, Mañas, M J, additional, Caro, A, additional, and Serena, C, additional
- Published
- 2024
- Full Text
- View/download PDF
3. P1193 NOD2 and Beyond: Unmasking Tobacco-Induced Epigenetic Changes in Crohn's Disease
- Author
-
Vañó, I, primary, Monfort Ferré, D, additional, Boronat Toscano, A, additional, Menacho, M, additional, Valldosera, G, additional, Caro, A, additional, Clua Ferré, L, additional, Suau, R, additional, Manyé, J, additional, and Serena, C, additional
- Published
- 2024
- Full Text
- View/download PDF
4. P074 Inflammatory Environment-Induced Transcriptomic Alterations in Crohn's Disease Adipose Stem Cells
- Author
-
Montfort-Ferré, D, primary, Boronat-Toscano, A, additional, Sánchez-Herrero, J F, additional, Caro, A, additional, Menacho, M, additional, Vañó-Segarra, I, additional, Martí, M, additional, Espina, B, additional, Pluvinet, R, additional, Cabrinety, L, additional, Abadia, C, additional, Ejarque, M, additional, Nuñez-Roa, C, additional, Maymo-Masip, E, additional, Sumoy, L, additional, Vendrell, J, additional, Fernández-Veledo, S, additional, and Serena, C, additional
- Published
- 2024
- Full Text
- View/download PDF
5. AB1645 CONTRACEPTION IN WOMEN WITH IMMUNE-MEDIATED INFLAMMATORY DISEASE
- Author
-
Rodriguez-Muguruza, S., primary, Castro Oreiro, S., additional, Poveda, M. J., additional, Del Castillo, N., additional, Menacho, M., additional, Valldosera, G., additional, Just, M., additional, Mohino, N., additional, and Fontova, R., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Smoking Suppresses the Therapeutic Potential of Adipose Stem Cells in Crohn’s Disease Patients through Epigenetic Changes
- Author
-
Universitat Rovira i Virgili, Boronat-Toscano, A; Vañó, I; Monfort-Ferré, D; Menacho, M; Valldosera, G; Caro, A; Espina, B; Mañas, MJ; Marti, M; Espin, E; Saera-Vila, A; Serena, C, Universitat Rovira i Virgili, and Boronat-Toscano, A; Vañó, I; Monfort-Ferré, D; Menacho, M; Valldosera, G; Caro, A; Espina, B; Mañas, MJ; Marti, M; Espin, E; Saera-Vila, A; Serena, C
- Abstract
Patients with Crohn’s disease (CD) who smoke are known to have a worse prognosis than never-smokers and a higher risk for post-surgical recurrence, whereas patients who quit smoking after surgery have significantly lower post-operative recurrence. The hypothesis was that smoking induces epigenetic changes that impair the capacity of adipose stem cells (ASCs) to suppress the immune system. It was also questioned whether this impairment remains in ex-smokers with CD. ASCs were isolated from non-smokers, smokers and ex-smokers with CD and their interactions with immune cells were studied. The ASCs from both smokers and ex-smokers promoted macrophage polarization to an M1 pro-inflammatory phenotype, were not able to inhibit T- and B-cell proliferation in vitro and enhanced the gene and protein expression of inflammatory markers including interleukin-1b. Genome-wide epigenetic analysis using two different bioinformatic approaches revealed significant changes in the methylation patterns of genes that are critical for wound healing, immune and metabolic response and p53-mediated DNA damage response in ASCs from smokers and ex-smokers with CD. In conclusion, cigarette smoking induces a pro-inflammatory epigenetic signature in ASCs that likely compromises their therapeutic potential.
- Published
- 2023
7. DOP078 Visceral and subcutaneous adipose tissues of Crohn’s disease patients contains bacteria
- Author
-
Serena, C, Terrón-Puig, M, Maymó-Masip, E, Queipo-Ortuño, M, Sabadell-Basallote, J, Rodríguez, M M, Nuñez-Roa, C, Menacho, M, Espin, E, Zorzano, A, Millan, M, Fernández-Veledo, S, and Vendrell, J
- Published
- 2018
- Full Text
- View/download PDF
8. P042 Succinate promotes the conversion from white to beige adipose tissue in Crohn’s Disease
- Author
-
Montfort-Ferré, D, primary, Menacho, M, additional, Caro, A, additional, Espina, B, additional, Boronat-Toscano, A, additional, Nuñez-Roa, C, additional, Martí, M, additional, Espin, E, additional, Vendrell, J, additional, Fernández-Veledo, S, additional, and Serena, C, additional
- Published
- 2022
- Full Text
- View/download PDF
9. P083 An integrative analysis of DNA methylation and RNA-Seq data in human adipose-stem cells of Crohn’s Disease patients with different clinical activity
- Author
-
Serena, C, primary, Montfort-Ferré, D, additional, Caro, A, additional, Menacho, M, additional, Espina, B, additional, Boronat-Toscano, A, additional, Martí, M, additional, Espín, E, additional, Millán, M, additional, Vendrell, J, additional, and Fernández-Veledo, S, additional
- Published
- 2022
- Full Text
- View/download PDF
10. P001 Succinate, a gut microbiota-derived metabolite, modulates the inflammatory status of the creeping fat in Crohn’s disease
- Author
-
Serena, C, primary, Monfort-Ferre, D, additional, Bautista, M, additional, Menacho, M, additional, Martí, M, additional, Espin, E, additional, Vendrell, J, additional, and Fernández-Veledo, S, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Adipose stem cells from patients with Crohn's disease show a distinctive DNA methylation pattern
- Author
-
Serena, C, Millan, M, Ejarque, M, Saera-Vila, A, Maymo-Masip, E, Nunez-Roa, C, Monfort-Ferre, D, Terron-Puig, M, Bautista, M, Menacho, M, Marti, M, Espin, E, Vendrell, J, and Fernandez-Veledo, S
- Subjects
Adipose tissue ,Methylome ,Epigenetics ,Gene expression ,Inflammatory bowel disease - Abstract
Background Crohn's disease (CD) is characterized by persistent inflammation and ulceration of the small or large bowel, and expansion of mesenteric adipose tissue, termed creeping fat (CF). We previously demonstrated that human adipose-derived stem cells (hASCs) from CF of patients with CD exhibit dysfunctional phenotypes, including a pro-inflammatory profile, high phagocytic capacity, and weak immunosuppressive properties. Importantly, these phenotypes persist in patients in remission and are found in all adipose depots explored including subcutaneous fat. We hypothesized that changes in hASCs are a consequence of epigenetic modifications. Methods We applied epigenome-wide profiling with a methylation array (Illumina EPIC/850k array) and gene expression analysis to explore the impact of CD on the methylation signature of hASCs isolated from the subcutaneous fat of patients with CD and healthy controls (n = 7 and 5, respectively; cohort I). Differentially methylated positions (p value cutoff < 1 x 10(-4) and ten or more DMPs per gene) and regions (inclusion threshold 0.2, p value cutoff < 1 x 10(-2) and more than 2 DMRs per gene) were identified using dmpfinder and Bumphunter (minfi), respectively. Changes in the expression of differentially methylated genes in hASCs were validated in a second cohort (n = 10/10 inactive and active CD and 10 controls; including patients from cohort I) and also in peripheral blood mononuclear cells (PBMCs) of patients with active/inactive CD and of healthy controls (cohort III; n = 30 independent subjects). Results We found a distinct DNA methylation landscape in hASCs from patients with CD, leading to changes in the expression of differentially methylated genes involved in immune response, metabolic, cell differentiation, and development processes. Notably, the expression of several of these genes in hASCs and PBMCs such as tumor necrosis factor alpha (TNFA) and PR domain zinc finger protein 16 (PRDM16) were not restored to normal (healthy) levels after disease remission. Conclusions hASCs of patients with CD exhibit a unique DNA methylation and gene expression profile, but the expression of several genes are only partially restored in patients with inactive CD, both in hASCs and PBMCs. Understanding how CD shapes the functionality of hASCs is critical for investigating the complex pathophysiology of this disease, as well as for the success of cell-based therapies.
- Published
- 2020
12. Adipose stem cells from patients with Crohn's disease show a distinctive DNA methylation pattern
- Author
-
Universitat Rovira i Virgili, Serena C; Millan M; Ejarque M; Saera-Vila A; Maymó-Masip E; Núñez-Roa C; Monfort-Ferré D; Terrón-Puig M; Bautista M; Menacho M; Martí M; Espin E; Vendrell J; Fernández-Veledo S, Universitat Rovira i Virgili, and Serena C; Millan M; Ejarque M; Saera-Vila A; Maymó-Masip E; Núñez-Roa C; Monfort-Ferré D; Terrón-Puig M; Bautista M; Menacho M; Martí M; Espin E; Vendrell J; Fernández-Veledo S
- Abstract
BACKGROUND: Crohn's disease (CD) is characterized by persistent inflammation and ulceration of the small or large bowel, and expansion of mesenteric adipose tissue, termed creeping fat (CF). We previously demonstrated that human adipose-derived stem cells (hASCs) from CF of patients with CD exhibit dysfunctional phenotypes, including a pro-inflammatory profile, high phagocytic capacity, and weak immunosuppressive properties. Importantly, these phenotypes persist in patients in remission and are found in all adipose depots explored including subcutaneous fat. We hypothesized that changes in hASCs are a consequence of epigenetic modifications. METHODS: We applied epigenome-wide profiling with a methylation array (Illumina EPIC/850k array) and gene expression analysis to explore the impact of CD on the methylation signature of hASCs isolated from the subcutaneous fat of patients with CD and healthy controls (n = 7 and 5, respectively; cohort I). Differentially methylated positions (p value cutoff < 1 × 10-4 and ten or more DMPs per gene) and regions (inclusion threshold 0.2, p value cutoff < 1 × 10-2 and more than 2 DMRs per gene) were identified using dmpfinder and Bumphunter (minfi), respectively. Changes in the expression of differentially methylated genes in hASCs were validated in a second cohort (n = 10/10 inactive and active CD and 10 controls; including patients from cohort I) and also in peripheral blood mononuclear cells (PBMCs) of patients with active/inactive CD and of healthy controls (cohort III; n = 30 independent subjects). RESULTS: We found a distinct DNA methylation landscape in hASCs from patients with CD, leading to changes in the expression of differentially methylated genes involved in immune response, metabolic, cell differentiation, and development
- Published
- 2020
13. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance
- Author
-
Iglesias, P., Arrieta, F., Piñera, M., Botella-Carretero, J. I., Balsa, J. A., Zamarrón, I., Menacho, M., Díez, J. J., Muñoz, T., and Vázquez, C.
- Published
- 2011
- Full Text
- View/download PDF
14. Facial exercise therapy for facial palsy: systematic review and meta-analysis
- Author
-
Pereira, L M, Obara, K, Dias, J M, Menacho, M O, Lavado, E L, and Cardoso, J R
- Published
- 2011
- Full Text
- View/download PDF
15. DOP84 Crohn’s disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
- Author
-
Serena, C, primary, Millan, M, additional, Ejarque, M, additional, Saera-Vila, A, additional, Monfort-Ferré, D, additional, Bautista, M, additional, Menacho, M, additional, Martí, M, additional, Espin, E, additional, Vendrell, J, additional, and Fernández-Veledo, S, additional
- Published
- 2020
- Full Text
- View/download PDF
16. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU
- Author
-
Chaparro, M, Garre, A, Ricart, E, Iglesias-Flores, E, Taxonera, C, Manosa, M, Mendoza, IV, Minguez, M, Arguelles, F, Parga, LD, Arroyo, M, Lopez-Sanroman, A, Tirado, MR, Guardiola, J, Arranz, MDM, Beltran, B, Barrio, J, Riestra, S, Garcia-Planella, E, Calvet, X, Alcain, G, Sicilia, B, Garcia, S, Esteve, M, Marquez, L, Salazar, LIF, Casbas, AG, Piqueras, M, Bermejo, F, Calle, JLP, Hinojosa, J, Perez, AR, Aldeguer, X, Sepulcre, MFG, Bujanda, L, Montiel, PM, Poyatos, RL, Gutierrez, CR, Merino, O, Cabriada, JL, Roncero, O, Cara, PR, Navarro-Llavat, M, Ber, Y, Madrigal, RE, Van Domselaar, M, Barreiro-de Acosta, M, Llao, J, Ramos, L, Riera, J, Villarin, AJL, Gonzalez, ER, Malaves, JMH, Villafranca, CM, Almela, P, Charro, M, de la Piscina, PR, Sese, E, Lacruz, AA, Khorrami, S, Alvarado, VJM, Gil, JL, Martinez, AMT, Villaroya, RP, Acevedo, J, Herola, AG, Villalba, LH, Munoz, E, Duran, MTN, Menacho, M, Lopez, VMN, Retamero, MD, Bernardo, D, Muriel, A, Domenech, E, Gisbert, JP, and ENEIDA Study Grp
- Abstract
Background Cohort studies comparing the characteristics of childhood-onset and adulthood-onset inflammatory bowel disease (IBD) in the biologics era are scarce. Aim To compare disease characteristics, the use of immunomodulators and biologic agents and the need for surgery between childhood- and adulthood-onset IBD. Methods Inflammatory bowel disease patients from the ENEIDA registry diagnosed between 2007 and 2017 were included. The childhood-onset cohort comprised patients diagnosed at 16 years. The cumulative incidences of immunosuppressive therapy, biologic therapy and surgery were estimated using Kaplan-Meier curves, compared by the log-rank test. Cox regression analysis was performed to identify potential predictive factors of treatment with immunosuppressants, biologic agents or surgery. Results The adulthood-onset cohort comprised 21 200 patients out of 20 354 (96%) and the childhood-onset cohort 846 (4%). Median follow-up was 54 months in the childhood-onset cohort and 38 months in the adulthood-onset cohort (P < 0.01). Proportions of Crohn's disease, ileocolonic involvement and inflammatory behaviour at diagnosis were higher in the childhood-onset cohort. In the multivariate analysis, after adjusting for sex, type of IBD, extraintestinal manifestations, family history and smoking habit, childhood-onset IBD was associated with higher risk of immunomodulator use (hazard ratio [HR] = 1.2, 95% confidence interval [95% CI] = 1.1-1.2) and higher probability of receiving biologic treatment (HR = 1.2, 95% CI = 1.1-1.3). However, childhood-onset IBD was not associated with higher risk of surgery (HR = 0.9, 95% CI = 0.8-1.2). Conclusions Childhood-onset IBD has differential characteristics and higher risk of treatment with immunomodulators and biologic agents, compared with adulthood-onset IBD. Nevertheless, paediatric IBD is not associated with higher risk of surgery.
- Published
- 2019
17. Occlusion of the superior mesenteric artery in a patient with Polycythemia vera: Resolution with percutaneous transluminal angioplasty
- Author
-
Bertrán, X., Muchart, J., Planas, R., Real, M. I., Ribera, J. M., Cabré, E., Menacho, M., and Gassull, M. A.
- Published
- 1996
- Full Text
- View/download PDF
18. DOP05 Adipose-derived stem cells from Crohn’s disease patients show antigen presenting cell-like properties
- Author
-
Serena, C, primary, Terrón-Puig, M, additional, Ejarque, M, additional, Algaba-Chueca, F, additional, Maymó-Masip, E, additional, Millan, M, additional, Menacho, M, additional, Espin, E, additional, Martí, M, additional, Fernández-Veledo, S, additional, and Vendrell, J, additional
- Published
- 2019
- Full Text
- View/download PDF
19. Micellar Effects on Dediazoniation and on Azo Coupling Reactions
- Author
-
Pazo-Llorente, Román, Rodriguez-Menacho, M<ce:sup loc='post">a</ce:sup> Carmen, González-Romero, Elisa, and Bravo-Díaz, Carlos
- Published
- 2002
- Full Text
- View/download PDF
20. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
- Author
-
Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, and Gisbert JP
- Subjects
Male ,Constriction, Pathologic ,Inflammatory bowel disease ,Gastroenterology ,Deprescriptions ,0302 clinical medicine ,Crohn Disease ,Recurrence ,Risk Factors ,Medicine ,Young adult ,Mesalamine ,Aged, 80 and over ,Incidence ,Incidence (epidemiology) ,Remission Induction ,Age Factors ,Middle Aged ,Antirheumatic Agents ,030220 oncology & carcinogenesis ,Retreatment ,Disease Progression ,Female ,030211 gastroenterology & hepatology ,Tumor necrosis factor alpha ,Adult ,medicine.medical_specialty ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Colon ,Young Adult ,03 medical and health sciences ,Ileum ,Internal medicine ,Humans ,Immunologic Factors ,Colitis ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Hepatology ,Tumor Necrosis Factor-alpha ,business.industry ,Proportional hazards model ,Adalimumab ,Retrospective cohort study ,Protective Factors ,Inflammatory Bowel Diseases ,medicine.disease ,Infliximab ,Discontinuation ,Methotrexate ,Colitis, Ulcerative ,business ,Follow-Up Studies - Abstract
OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. RESULTS: A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confi dence interval (CI)= 1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI= 1.07-3.37) or discontinuation because of adverse events (HR= 2.33; 95% CI= 1.27-2.02) vs. a top-down strategy, colonic localization (HR= 1.51; 95% CI= 1.13-2.02) vs. ileal, and stricturing behavior (HR= 1.5; 95% CI= 1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn's disease patients, whereas treatment with immunomodulators after discontinuation (HR= 0.67; 95% CI= 0.51-0.87) and age (HR= 0.98; 95% CI= 0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe. CONCLUSIONS: The incidence rate of infl ammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identifi ed. Retreatment with the same anti-TNF drug was effective and safe.
- Published
- 2017
21. P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU
- Author
-
Chaparro, M, primary, Garre, A, additional, Ricart, E, additional, García-Sánchez, V, additional, Taxonera, C, additional, Mañosa, M, additional, Vera Mendoza, I, additional, Mínguez, M, additional, Argüelles, F, additional, De Castro Parga, L, additional, Arroyo, M, additional, López-San Román, A, additional, Rivero Tirado, M, additional, Guardiola, J, additional, Martín Arranz, M D, additional, Beltrán, B, additional, Barrio, J, additional, Riestra, S, additional, García-Planella, E, additional, Calvet, X, additional, Alcaín, G, additional, Sicilia, B, additional, García, S, additional, Esteve, M, additional, Márquez, L, additional, Fernández Salazar, L, additional, Gutiérrez Casbas, A, additional, Piqueras, M, additional, Guerra, I, additional, Pérez Calle, J L, additional, Hinojosa, J, additional, Rodríguez, A, additional, Aldeguer, X, additional, García-Sepulcre, M, additional, Bujanda, L, additional, Martínez Montiel, P, additional, Llorente Poyatos, R, additional, Rodríguez Gutiérrez, C, additional, Merino, O, additional, Cabriada, J L, additional, Roncero, O, additional, Romero Cara, P, additional, Navarro-Llavat, M, additional, Ber, Y, additional, Madrigal, R, additional, Van Domselaar, M, additional, Barreiro-de Acosta, M, additional, Llao, J, additional, Ramos, L, additional, Riera, J, additional, Lucendo Villarín, A J, additional, Rodríguez González, E, additional, Huguet Malavés, J M, additional, Muñoz Villafranca, C, additional, Almela, P, additional, Charro, M, additional, Ramírez de la Piscina, P, additional, Sese, E, additional, Abad Lacruz, Á, additional, Khorrami, S, additional, Morales Alvarado, V J, additional, Legido Gil, J, additional, Trapero Martínez, A M, additional, Pajares, R, additional, Acevedo, J, additional, García Herola, A, additional, Hernández Villalba, L, additional, Muñoz, E, additional, Novella Durán, M T, additional, Menacho, M, additional, Navas López, V M, additional, Retamero, M D, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2018
- Full Text
- View/download PDF
22. Crohn's Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to Inflammasome Activation
- Author
-
Universitat Rovira i Virgili, Serena C., Keiran N., Madeira A., Maymó-Masip E., Ejarque M., Terrón-Puig M., Espin E., Martí M., Borruel N., Guarner F., Menacho M., Zorzano A., Millan M., Fernández-Veledo S., Vendrell J., Universitat Rovira i Virgili, and Serena C., Keiran N., Madeira A., Maymó-Masip E., Ejarque M., Terrón-Puig M., Espin E., Martí M., Borruel N., Guarner F., Menacho M., Zorzano A., Millan M., Fernández-Veledo S., Vendrell J.
- Abstract
Crohn's disease (CD) is characterized by the expansion of mesenteric fat, also known as "creeping fat." We explored the plasticity and immune properties of adipose-derived stem cells (ASCs) in the context of CD as potential key players in the development of creeping fat. Mesenteric CD-derived ASCs presented a more proliferative, inflammatory, invasive, and phagocytic phenotype than equivalent cells from healthy donors, irrespective of the clinical stage. Remarkably, ASCs from the subcutaneous depot of patients with CD also showed an activated immune response that was associated with a reduction in their immunosuppressive properties. The invasive phenotype of mesenteric CD ASCs was governed by an inflammasome-mediated inflammatory state since blocking inflammasome signaling, mainly the secretion of interleukin-1?, reversed this characteristic. Thus, CD alters the biological functions of ASCs as adipocyte precursors, but also their immune properties. Selection of ASCs with the best immunomodulatory properties is advocated for the success of cell-based therapies.Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
- Published
- 2017
23. CONTRACEPTION IN WOMEN WITH IMMUNEMEDIATED INFLAMMATORY DISEASE.
- Author
-
Rodriguez-Muguruza, S., Oreiro, S. Castro, Poveda, M. J., Del Castillo, N., Menacho, M., Valldosera, G., Just, M., Mohino, N., and Fontova, R.
- Published
- 2023
- Full Text
- View/download PDF
24. I257 THE BOLIVIAN EXPERIENCE IN ATTENDING SEXUAL VIOLENCE
- Author
-
Mostajo, D., primary, Inochea, V., additional, Mostajo-Radji, M.A., additional, Fuchtner, C., additional, and Menacho, M., additional
- Published
- 2012
- Full Text
- View/download PDF
25. 1067 EFFECT OF IRON DEPLETION ON INSULIN RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C AND HYPERFERRITINEMIA
- Author
-
Montoliu, S., primary, Pardo, A., additional, Vargas, M., additional, Papo, M., additional, Menacho, M., additional, Balleste, B., additional, Abadia, C., additional, and Quer, J.C., additional
- Published
- 2010
- Full Text
- View/download PDF
26. Cytomegalovirus Infection in Patients With Inflammatory Bowel Disease
- Author
-
Vega, R., primary, Bertrán, X., additional, Menacho, M., additional, Domènech, E., additional, Moreno de Vega, V., additional, Hombrados, M., additional, Cabré, E., additional, Ojanguren, I., additional, and Gassull, M. A., additional
- Published
- 1999
- Full Text
- View/download PDF
27. Factors Related to the Presence of IgA Class Antineutrophil Cytoplasmic Antibodies in Ulcerative Colitis
- Author
-
Esteve, M, primary, Mallolas, J, additional, Klaassen, J, additional, Abad-Lacruz, A, additional, Gonzàlez-Huix, F, additional, Cabré, E, additional, Fernández-Bañares, F, additional, Menacho, M, additional, Condom, E, additional, Martí-Ragué, J, additional, and Gassull, M A, additional
- Published
- 1998
- Full Text
- View/download PDF
28. P.86 Mucosal fatty acid pattern in inflammatory boweldisease patients
- Author
-
Esteve, M., primary, Navarro, E., additional, Fernández-Bañares, F., additional, Cabré, E., additional, Pastor, C., additional, Aldeguer, X., additional, Menacho, M., additional, Boix, J., additional, and Gassull, M.A., additional
- Published
- 1997
- Full Text
- View/download PDF
29. Occlusion of the superior mesenteric artery in a patient with Polycythemia vera: Resolution with percutaneous transluminal angioplasty
- Author
-
Bertr�n, X., primary, Muchart, J., additional, Planas, R., additional, Real, M. I., additional, Ribera, J. M., additional, Cabr�, E., additional, Menacho, M., additional, and Gassull, M. A., additional
- Published
- 1996
- Full Text
- View/download PDF
30. Time-of-Day Effect on Hip Flexibility Associated with the Modified Sit-and-Reach Test in Males.
- Author
-
Guariglia, D. A., Pereira, L. M., Dias, J. M., Pereira, H. M., Menacho, M. O., Silva, D. A., Cyrino, E. S., and Cardoso, J. R.
- Subjects
HIP joint physiology ,ANALYSIS of variance ,KINEMATICS ,PHYSICAL fitness ,RESEARCH funding ,STATISTICS ,STRETCH (Physiology) ,TIME ,INTER-observer reliability ,REPEATED measures design ,DATA analysis software - Abstract
Flexibility is a key component of physical fitness. It has been suggested that measures of physical fitness components may vary throughout the day. The aim of this study was to analyse the effects of the time of day on flexibility performance. 26 men (mean age = 25.4 years, SD = 2.5) were evaluated by hip flexion on kinematic analysis and also by an absolute score in the modified Sit-and-Reach test during a repeated measure design. This was done during 3 experimental sessions, which took place at 8:00 a.m., 1:00 p.m. and 6:00 p.m., in random order. All subjects were previously familiarized with the test parameters. There was a diurnal variation only in the modified Sit-and-Reach test score between 8:00 a.m and 6:00 p.m. ( P = 0.01). There was no significant difference in the hip kinematic analysis between hours. These findings suggest that flexibility performance in the modified Sit-and-Reach test, in absolute scores, is affected by the time of day, with higher performance in the evening. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
31. Spontaneous bacterial periotonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes
- Author
-
Llovet, J. M., Rodriguez-Iglesia, P., Moitinbo, E., Planas, R., Bataller, R., Navasa, M., Menacho, M., Pardo, A., Castells, A., and Cabre, E.
- Published
- 1997
- Full Text
- View/download PDF
32. Los síntomas oculares en la encefalitis letárgicas
- Author
-
Menacho, M.
- Published
- 1919
33. Manifestaciones gripales observadas en el aparato visual durante las epidemias del año 1918 en Barcelona
- Author
-
Menacho, M.
- Published
- 1919
34. La aptitud psicovisual de los motoristas
- Author
-
Menacho, M.
- Published
- 1930
35. comentarios a propósito de un caso de iritis en un operado de glaucoma
- Author
-
Menacho, M.
- Published
- 1919
36. Diagnóstico topográfico de las parálisis de los músculos del ojo
- Author
-
Menacho, M.
- Published
- 1925
37. La proscripción de los emigrantes tracomatosos en el continente americano
- Author
-
Menacho, M.
- Published
- 1917
38. Un caso de abceso circunscripto primitivo de la esclerótica (con presentación del paciente)
- Author
-
Menacho, M.
- Published
- 1917
39. Movimientos asociados del párpado superior y de la masticación (Fenómenos de Marcos GUNN)
- Author
-
Menacho, M.
- Published
- 1917
40. Cuota visual necesaria a los motoristas
- Author
-
Menacho, M.
- Published
- 1917
41. Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU
- Author
-
Chaparro, M., Garre, A., Ricart, E., Garcia-Sanchez, V., Taxonera, C., Manosa, M., Vera Mendoza, I., Minguez, M., Arguelles, F., Castro Parga, L., Arroyo, M., Lopez-San Roman, A., Rivero Tirado, M., Guardiola, J., Martin Arranz, M. D., Beltran, B., Barrio, J., Riestra, S., Garcia-Planella, E., Calvet, X., Alcain, G., Sicilia, B., Garcia, S., Esteve, M., Marquez, L., Fernandez Salazar, L., Gutierrez Casbas, A., Piqueras, M., Guerra, I., Perez Calle, J. L., Hinojosa, J., Rodriguez, A., Aldeguer, X., Garcia-Sepulcre, M., Bujanda, L., Martinez Montiel, P., Llorente Poyatos, R., Rodriguez Gutierrez, C., Merino, O., Cabriada, J. L., Octavio Roncero, Romero Cara, P., Navarro-Llavat, M., Ber, Y., Madrigal, R., Domselaar, M., Barreiro-De Acosta, M., Llao, J., Ramos, L., Riera, J., Lucendo Villarin, A. J., Rodriguez Gonzalez, E., Huguet Malaves, J. M., Munoz Villafranca, C., Almela, P., Charro, M., Ramirez La Piscina, P., Sese, E., Abad Lacruz, A., Khorrami, S., Morales Alvarado, V. J., Legido Gil, J., Trapero Martinez, A. M., Pajares, R., Acevedo, J., Garcia Herola, A., Hernandez Villalba, L., Munoz, E., Novella Duran, M. T., Menacho, M., Navas Lopez, V. M., Retamero, M. D., Domenech, E., and Gisbert, J. P.
42. Azathioprine Is Useful in Maintaining Long-Term Remission Induced by Intravenous Cyclosporine in Steroid-Refractory Severe Ulcerative Colitis.
- Author
-
Fernández-Bañares, F., Bertrán, X., Esteve-Comas, M., Cabré, E., Menacho, M., Humbert, P., Planas, R., and Gassull, M. A.
- Subjects
CYCLOSPORINE ,ULCERATIVE colitis ,IMMUNOSUPPRESSIVE agents ,INFLAMMATORY bowel diseases ,COLON diseases - Abstract
Background/Aim: Therapeutic regimens with intravenous (i.v.) cyclosporine followed by oral cyclosporine maintenance therapy reduce the need for immediate surgery in steroid-refractory severe ulcerative colitis, but the short-term colectomy rate is still as high as 70%. We report our experience with long-term azathioprine maintenance therapy in a small series of ulcerative colitis patients with i.v. cyclosporine-induced remission. Methods and Results: Twelve of thirteen patients with severe ulcerative colitis refractory to i.v. prednisone (1 mg/kg/day for at least 10 days) went into remission after adding i.v. cyclosporine (4 mg/kg/day) and are the subjects of this report. After a discouraging initial experience with oral cyclosporine plus mesalazine as maintenance therapy in the first four patients, we treated the following patients with azathioprine plus mesalazine starting immediately after response to i.v. cyclosporine was obtained. Overall, only 1 of 10 patients treated with azathioprine relapsed after a mean follow-up of 16.3 months (range: 6-48). Moreover, this relapse probably occurred when the drug was still not therapeutically active because, after reinducing remission with oral prednisone, the patient remained symptomless on azathioprine. Steroids could be discontinued in all patients. Conclusions: The relapse rate on maintenance therapy with azathioprine (10%) is a figure considerably lower than that previously reported with oral cyclosporine. This promising experience should be confirmed in ran-domized controlled trials. [ABSTRACT FROM AUTHOR]
- Published
- 1996
43. The Gut Microbiota Metabolite Succinate Promotes Adipose Tissue Browning in Crohn’s Disease
- Author
-
Monfort-Ferré, Diandra, Caro, Aleidis, Menacho, Margarita, Marti-Gallostra, Marc, Espina, Beatriz, Boronat-Toscano, Albert, Núñez Roa, Catalina, Seco, Jesús, Bautista, Michelle, Espín, Eloy, Megía, Ana, Vendrell, Joan, Fernández-Veledo, Sonia, Serena, Carolina, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Monfort-Ferré D, Boronat-Toscano A] Hospital Universitari de Tarragona Joan XXIII, Institut d’Investigació Sanitària Pere Virgili, Tarragona, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. [Caro A, Espina B] Colorectal Surgery Unit, Hospital Universitari Joan XXIII, Tarragona, Spain. [Menacho M] Digestive Unit, Hospital Universitari Joan XXIII, Tarragona, Spain. [Martí M, Espín E] Unitat de Cirurgia de Còlon i Recte, Servei de Cirurgia General, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
fenómenos microbiológicos::microbiota::microbiota intestinal [FENÓMENOS Y PROCESOS] ,Microbiological Phenomena::Microbiota::Gastrointestinal Microbiome [PHENOMENA AND PROCESSES] ,Adipose Tissue, White ,Creeping fat ,Succinic Acid ,Gastroenterology ,Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES] ,Bacteria translocation ,General Medicine ,Crohn, Malaltia de ,Beige adipose tissue ,enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES] ,Gastrointestinal Microbiome ,Succinic acid ,Teixit adipós ,Tissues::Connective Tissue::Adipose Tissue [ANATOMY] ,SUCNR1 ,Crohn Disease ,Adipose Tissue ,Humans ,Intestins - Microbiologia ,tejidos::tejido conectivo::tejido adiposo [ANATOMÍA] ,Uncoupling Protein 1 - Abstract
Succinic acid; Bacteria translocation; Beige adipose tissue Àcid succínic; Translocació de bacteris; Teixit adipós beige Ácido succínico; Translocación de bacterias; Tejido adiposo beige Background and Aims Crohn’s disease [CD] is associated with complex microbe–host interactions, involving changes in microbial communities, and gut barrier defects, leading to the translocation of microorganisms to surrounding adipose tissue [AT]. We evaluated the presence of beige AT depots in CD and questioned whether succinate and/or bacterial translocation promotes white-to-beige transition in adipocytes. Methods Visceral [VAT] and subcutaneous [SAT] AT biopsies, serum and plasma were obtained from patients with active [n = 21] or inactive [n = 12] CD, and from healthy controls [n = 15]. Adipose-derived stem cells [ASCs] and AT macrophages [ATMs] were isolated from VAT biopsies. Results Plasma succinate levels were significantly higher in patients with active CD than in controls and were intermediate in those with inactive disease. Plasma succinate correlated with the inflammatory marker high-sensitivity C-reactive protein. Expression of the succinate receptor SUCNR1 was higher in VAT, ASCs and ATMs from the active CD group than from the inactive or control groups. Succinate treatment of ASCs elevated the expression of several beige AT markers from controls and from patients with inactive disease, including uncoupling protein-1 [UCP1]. Notably, beige AT markers were prominent in ASCs from patients with active CD. Secretome profiling revealed that ASCs from patients with active disease secrete beige AT-related proteins, and co-culture assays showed that bacteria also trigger the white-to-beige switch of ASCs from patients with CD. Finally, AT depots from patients with CD exhibited a conversion from white to beige AT together with high UCP1 expression, which was corroborated by in situ thermal imaging analysis. Conclusions Succinate and bacteria trigger white-to-beige AT transition in CD. Understanding the role of beige AT in CD might aid in the development of therapeutic or diagnostic interventions. This study was supported by grants from the Spanish Ministry of Science and Innovation [PI18/00037 (Instituto de Salud Carlos III, ISCIII) to C.S.; PI17/01503 and PI20/00338 (ISCIII) to J.V. and RTI2018-093919 to S.F.-V.], co-financed by the European Regional Development Fund [ERDF] and a European Crohn’s and Colitis Organization grant to C.S. The Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders [CIBERDEM] [CB07708/0012] is an initiative of the Instituto de Salud Carlos ISCIII acknowledges support from the ‘Ramón y Cajal’ programme from the Ministerio de Educación y Ciencia [RYC2013-13186], co-financed by the ERDF. S.F.-V. acknowledge support from the ‘Miguel Servet’ tenure track programme [CP10/00438, CPII16/0008] from the Fondo de Investigación Sanitaria, co-financed by the ERDF. D.M.-F. acknowledges support from PERIS-PFI-Salut SLT01720000021.
- Published
- 2022
44. Smoking Suppresses the Therapeutic Potential of Adipose Stem Cells in Crohn’s Disease Patients through Epigenetic Changes
- Author
-
Albert Boronat-Toscano, Irene Vañó, Diandra Monfort-Ferré, Margarita Menacho, Gemma Valldosera, Aleidis Caro, Beatriz Espina, Maria José Mañas, Marc Marti, Eloy Espin, Alfonso Saera-Vila, Carolina Serena, Institut Català de la Salut, [Boronat-Toscano A, Vañó I, Monfort-Ferré D] Hospital Universitari de Tarragona Joan XXIII, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain. [Menacho M, Valldosera G] Digestive Unit, Hospital Universitari Joan XXIII, Tarragona, Spain. [Caro A] Colorectal Surgery Unit, Hospital Universitari Joan XXIII, Tarragona, Spain. [Marti M, Espin E] Unitat de Cirurgia de Còlon i Recte, Servi de Cirurgia General i Digestiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Intestins - Inflamació - Tractament ,Behavior and Behavior Mechanisms::Behavior::Smoking [PSYCHIATRY AND PSYCHOLOGY] ,conducta y mecanismos de la conducta::conducta::fumar [PSIQUIATRÍA Y PSICOLOGÍA] ,fenómenos genéticos::regulación de la expresión génica::epigénesis genética [FENÓMENOS Y PROCESOS] ,Aparell digestiu - Malalties - Tractament ,Genetic Phenomena::Gene Expression Regulation::Epigenesis, Genetic [PHENOMENA AND PROCESSES] ,Cells::Stem Cells [ANATOMY] ,DNA methylation ,tobacco ,cigarette ,macrophages ,cell therapy ,adipose tissue ,inflammatory bowel diseases ,chronic inflammatory disease ,immune cells ,differentially methylated regions ,Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES] ,General Medicine ,Cèl·lules mare ,células::células madre [ANATOMÍA] ,enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES] - Abstract
Cell therapy; Chronic inflammatory disease; Cigarette Terapia celular; Enfermedad inflamatoria crónica; Cigarrillo Teràpia cel·lular; Malaltia inflamatòria crònica; Cigarret Patients with Crohn’s disease (CD) who smoke are known to have a worse prognosis than never-smokers and a higher risk for post-surgical recurrence, whereas patients who quit smoking after surgery have significantly lower post-operative recurrence. The hypothesis was that smoking induces epigenetic changes that impair the capacity of adipose stem cells (ASCs) to suppress the immune system. It was also questioned whether this impairment remains in ex-smokers with CD. ASCs were isolated from non-smokers, smokers and ex-smokers with CD and their interactions with immune cells were studied. The ASCs from both smokers and ex-smokers promoted macrophage polarization to an M1 pro-inflammatory phenotype, were not able to inhibit T- and B-cell proliferation in vitro and enhanced the gene and protein expression of inflammatory markers including interleukin-1b. Genome-wide epigenetic analysis using two different bioinformatic approaches revealed significant changes in the methylation patterns of genes that are critical for wound healing, immune and metabolic response and p53-mediated DNA damage response in ASCs from smokers and ex-smokers with CD. In conclusion, cigarette smoking induces a pro-inflammatory epigenetic signature in ASCs that likely compromises their therapeutic potential. This study was supported by a grant from the Spanish Ministry of Economy and Competitiveness (PI18/00037 to CS), co-financed by the European Regional Development Fund (ERDF). C.S. acknowledges support from “Ramón y Cajal’ program from the Ministerio de Educación y Ciencia (RYC2013-13186), co-financed by the ERDF. A.B.-T. acknowledge support from PI-AGAUR 2022-B00577. I.V. acknowledges support from INVESTIGO-AGAUR (100036TC2). D.M.-F. acknowledges support from PERIS-PFI-Salut SLT01720000021.
- Published
- 2023
45. Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn’s Disease
- Author
-
Boronat-Toscano, Albert, Monfort-Ferré, Diandra, Menacho, Margarita, Caro, Aleidis, Bosch Príncep, Ramon, Espina, Beatriz, Algaba, Ferran, Saera-Vila, Alfonso, Moliné, Alicia, Marti-Gallostra, Marc, Espin-Basany, Eloy, Millan, Mónica, Serena, Carolina, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Boronat-Toscano A, Monfort-Ferré D] Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain. [Menacho M] Digestive Unit, Hospital Universitari Joan XXIII, Tarragona, Spain. [Caro A, Espina B] Colorectal Surgery Unit, Hospital Universitari Joan XXIII, Tarragona, Spain. [Bosch R] Department of Pathology, Oncological Pathology and Bioinformatics Research Group, Hospital de Tortosa Verge de la Cinta—IISPV, Tortosa, Spain. [Marti M, Espin E] Unitat de Cirurgia de Còlon i Recte, Servei de Cirurgia General, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
TNF ,Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES] ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Adipose tissue ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Catalysis ,Inorganic Chemistry ,Crohn Disease ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Productes biològics - Ús terapèutic ,Spectroscopy ,ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD] ,Inflammation ,Biological Products ,Organic Chemistry ,Adalimumab ,Creeping fat ,General Medicine ,mezclas complejas::productos biológicos [COMPUESTOS QUÍMICOS Y DROGAS] ,Infliximab ,enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES] ,Computer Science Applications ,Crohn, Malaltia de - Tractament ,Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE] ,Adipose Tissue ,Quality of Life ,Complex Mixtures::Biological Products [CHEMICALS AND DRUGS] ,Qualitat de vida - Avaluació ,adipose tissue ,infliximab ,adalimumab ,creeping fat - Abstract
Adalimumab; Adipose tissue; Infliximab Adalimumab; Tejido adiposo; Infliximab Adalimumab; Teixit adipós; Infliximab Anti-TNF biologics have been shown to markedly improve the quality of life for patients with Crohn’s disease (CD), yet one-third of patients fail to benefit from this treatment. Patients with CD develop a characteristic wrapping of visceral adipose tissue (VAT) in the inflamed intestinal area, termed creeping fat, and it is known that adipose tissue expansion influences the efficacy of anti-TNF drugs. We questioned whether anti-TNF therapies impact the creeping fat in CD, which might affect the outcome of the disease. Adipose tissue biopsies were obtained from a cohort of 14 patients with CD that received anti-TNF drugs and from 29 non-anti-TNF-treated patients (control group) matched by sex, age, and body mass index undergoing surgical interventions for symptomatic complications. We found that anti-TNF therapies restored adipose tissue morphology and suppressed immune cell infiltration in the creeping fat. Additionally, anti-TNF treatments appeared to markedly improve the pro-inflammatory phenotype of adipose-tissue macrophages and adipose-tissue-derived stem cells. Our study provides evidence that anti-TNF medications influence immune cells and progenitor cells in the creeping of patients with CD, suppressing inflammation. We propose that perilesional VAT should be considered when administering anti-TNF therapy in patients with CD. This study was supported by a grant from the Spanish Ministry of Economy and Competitiveness (PI18/00037 to C.S.), co-financed by the European Regional Development Fund (ERDF). C.S. acknowledges support from the “Ramón y Cajal” program from the Ministerio de Educación y Ciencia (RYC2013-13186), co-financed by the ERDF. A.B.-T. acknowledges support from PI-AGAUR 2022-B00577. D.M.-F. acknowledges support from PERIS-PFI-Salut SLT01720000021.
- Published
- 2022
46. Microbial Signature in Adipose Tissue of Crohn's Disease Patients
- Author
-
Marc Martí, Eloy Espin, Margarida Terrón-Puig, Aleidis Caro, Catalina Núñez-Roa, Joan Vendrell, Elsa Maymó-Masip, Maribel Queipo-Ortuño, M. Mar Rodríguez, Diandra Monfort-Ferré, Sonia Fernández-Veledo, Monica Millan, Carolina Serena, Lidia Sánchez-Alcoholado, Francisco J. Tinahones, Michelle Bautista, Margarita Menacho, Beatriz Espina, [Serena,C, Monfort-Ferré,D, Terrón-Puig,M, Núñez-Roa,C, Maymó-Masip,E, Rodriguez,MM, Fernández-Veledo,S, Vendrell,J] Hospital Universitari de Tarragona Joan XXIII, Institut d’Investigació Sanitària Pere Virgili Universitat Rovira i Virgili, Tarragona, Spain. [Serena,C, Vendrell,J] CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. [Queipo-Ortuño,M, Sanchez-Alcoholado,L] CIBER de Obesidad y Nutrición (CIBERObN), Instituto de Salud Carlos III, Madrid, Spain. [Queipo-Ortuño,M, Sanchez-Alcoholado,L] Unidad de Gestión Clínica Intercentros de Oncología Medica, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-CIMES-UMA, Málaga, Spain. [Millan,M, Caro,A, Espina,B] Colorectal Surgery Unit, Hospital Universitari Joan XXIII, Tarragona, Spain. [Millan,M] Colorectal Surgery Unit, Hospital Universitari La Fe, Valencia, Spain. [Menacho,M, Bautista,M] Digestive Unit, University Hospital Joan XXIII, IISPV, Tarragona, Spain. [Tinahones,FJ] Endocrinology and Nutrition Department, Biomedical Research Institute from Malaga (IBIMA), University Hospital Virgen de la Victoria of Malaga, Malaga University, Málaga, Spain. [Espin,E, Martí,M] Colorectal Surgery Unit, General Surgery Service, Valle Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain. [Vendrell,J] Medicine and Surgery Department, School of Medicine, Universitat Rovira i Virgili, Tarragona, Spain., This study was supported by grants from the Spanish Ministry of Economy and Competitiveness (PI18/00037, PI15/00143 to C.S., PI14/00228 and PI17/01503 to J.V., and PI15/00256 to M.Q.-O., RTI2018-093919 to S.F.-V.), co-financed by the European Regional Development Fund (ERDF) and a European Crohn’s and Colitis Organization grant to C.S. The Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM) (CB07708/0012) is an initiative of the Instituto de Salud Carlos III. C.S. acknowledges support from 'Ramón y Cajal' program from the Ministerio de Educación y Ciencia (RYC2013-13186), co-financed by the ERDF. S.F.-V. and M.Q.-O. acknowledge support from the 'Miguel Servet' tenure track program (CP10/00438, CPII16/0008, and and CPI13/00003, respectively) from the Fondo de Investigación Sanitaria, co-financed by the ERDF.M.Q.-O. belongs to the regional 'Nicolas Monardes' research program of the Consejería de Salud (C-0030-2018), Junta de Andalucía, Spain, and M.T.-P. is a recipient of a Río Hortega IISCIII fellowship (CM18/00029), both co-financed by the ERDF.
- Subjects
Lipopolysaccharide biosynthesis ,Phenomena and Processes::Metabolic Phenomena::Metabolism::Metabolic Networks and Pathways [Medical Subject Headings] ,lcsh:Medicine ,Adipose tissue ,Gut flora ,lipopolysaccharide biosynthesis ,Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::DNA::DNA, Bacterial [Medical Subject Headings] ,medicine.disease_cause ,Inflammatory bowel disease ,tissue microbiota ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,16S sequencing ,0302 clinical medicine ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Hyperplasia [Medical Subject Headings] ,0303 health sciences ,Crohn's disease ,biology ,Microbiota ,General Medicine ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Albumins::C-Reactive Protein [Medical Subject Headings] ,Organisms::Bacteria::Proteobacteria [Medical Subject Headings] ,Fusobacterium ,Anatomy::Tissues::Connective Tissue::Adipose Tissue [Medical Subject Headings] ,Tissue microbiota ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Health Surveys::Health Status Indicators::Patient Acuity::Severity of Illness Index [Medical Subject Headings] ,030211 gastroenterology & hepatology ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Dysbiosis [Medical Subject Headings] ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Nerve Tissue Proteins::S100 Proteins::Leukocyte L1 Antigen Complex [Medical Subject Headings] ,Tejido adiposo ,Article ,03 medical and health sciences ,inflammatory bowel disease ,Lipopolisacáridos ,medicine ,Escherichia coli ,Microbiome ,Enfermedad de Crohn ,030304 developmental biology ,business.industry ,lcsh:R ,Chemicals and Drugs::Lipids::Lipopolysaccharides [Medical Subject Headings] ,Creeping fat ,Pathogenic bacteria ,medicine.disease ,biology.organism_classification ,digestive system diseases ,ARN ribosómico 16S ,PICRUSt analysis ,Tejidos ,Enfermedad inflamatoria intestinal ,Immunology ,creeping fat ,Calprotectin ,business ,Dysbiosis ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings] - Abstract
Crohn&rsquo, s disease (CD) is characterized by compromised immune tolerance to the intestinal commensal microbiota, intestinal barrier inflammation, and hyperplasia of creeping fat (CF) and mesenteric adipose tissue (AT), which seems to be directly related to disease activity. Gut microbiota dysbiosis might be a determining factor in CD etiology, manifesting as a low microbial diversity and a high abundance of potentially pathogenic bacteria. We tested the hypothesis that CF is a reservoir of bacteria through 16S-rRNA sequencing of several AT depots of patients with active and inactive disease and controls. We found a microbiome signature within CF and mesenteric AT from patients, but not in subcutaneous fat. We failed to detect bacterial DNA in any fat depot of controls. Proteobacteria was the most abundant phylum in both CF and mesenteric AT, and positively correlated with fecal calprotectin/C-reactive protein. Notably, the clinical status of patients seemed to be related to the microbiome signature, as those with the inactive disease showed a reduction in the abundance of pathogenic bacteria. Predictive functional profiling revealed many metabolic pathways including lipopolysaccharide biosynthesis and sulfur metabolism overrepresented in active CD relative to that in inactive CD. Our findings demonstrate that microbiota dysbiosis associated with CD pathophysiology is reflected in AT and might contribute to disease severity.
- Published
- 2020
47. Genome-wide DNA Methylome and Transcriptome Profiling Reveals Key Genes Involved in the Dysregulation of Adipose Stem Cells in Crohn's Disease.
- Author
-
Monfort-Ferré D, Boronat-Toscano A, Sánchez-Herrero JF, Caro A, Menacho M, Vañó-Segarra I, Martí M, Espina B, Pluvinet R, Cabrinety L, Abadia C, Ejarque M, Nuñez-Roa C, Maymo-Masip E, Sumoy L, Vendrell J, Fernández-Veledo S, and Serena C
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Epigenome, Stem Cells metabolism, Genome-Wide Association Study, Epigenesis, Genetic, Case-Control Studies, Crohn Disease genetics, Crohn Disease metabolism, Crohn Disease pathology, DNA Methylation, Gene Expression Profiling methods, Adipose Tissue metabolism
- Abstract
Background and Aims: Crohn's disease [CD] is characterised by the expansion of mesenteric adipose tissue [MAT], named creeping fat [CF], which seems to be directly related to disease activity. Adipose-stem cells [ASCs] isolated from the CF of patients with CD are extremely pro-inflammatory, which persists during disease remission. We hypothesised that the dysfunctional ASCs in CD accumulate epigenetic modifications triggered by the inflammatory environment, that could serve as molecular markers., Methods: Genome-wide DNA methylome and transcriptome profiling were performed in ASCs isolated from MAT biopsies of patients with active and inactive disease and from non-Crohn's disease patients [non-CD]. A validation cohort was used to test the main candidate genes via quantitative polymerase chain reaction in other fat depots and immune cells., Results: We found differences in DNA methylation and gene expression between ASCs isolated from patients with CD and from non-CD subjects, but we found no differences related to disease activity. Pathway enrichment analysis revealed that oxidative stress and immune response were significantly enriched in active CD, and integration analysis identified MAB21L2, a cell fate-determining gene, as the most affected gene in CD. Validation analysis confirmed the elevated gene expression of MAB21L2 in MAT and in adipose tissue macrophages in active CD. We also found a strong association between expression of the calcium channel subunit gene CACNA1H and disease remission, as CACNA1H expression was higher in ASCs and MAT from patients with inactive CD, and correlates negatively with C-reactive protein in peripheral blood mononuclear cells., Conclusion: We identified a potential gene signature of CD in ASCs obtained from MAT. Integration analysis highlighted two novel genes demonstrating a negative correlation between promoter DNA methylation and transcription: one linked to ASCs in CD [MAB21L2] and the other [CACNA1H] related to disease remission., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
48. Evidence of bottom-up homeostatic modulation induced taVNS during emotional and Go/No-Go tasks.
- Author
-
Camargo L, Pacheco-Barrios K, Gianlorenço AC, Menacho M, Choi H, Song JJ, and Fregni F
- Subjects
- Humans, Male, Female, Adult, Double-Blind Method, Young Adult, Executive Function physiology, Alpha Rhythm physiology, Evoked Potentials physiology, Transcutaneous Electric Nerve Stimulation methods, Inhibition, Psychological, Emotions physiology, Vagus Nerve Stimulation methods, Electroencephalography methods
- Abstract
Bilateral transcutaneous auricular vagus nerve stimulation (taVNS) - a non-invasive neuromodulation technique - has been investigated as a safe and feasible technique to treat many neuropsychiatric conditions. such as epilepsy, depression, anxiety, and chronic pain. Our aim is to investigate the effect of taVNS on neurophysiological processes during emotional and Go/No-Go tasks, and changes in frontal alpha asymmetry. We performed a randomized, double-blind, sham-controlled trial with 44 healthy individuals who were allocated into two groups (the active taVNS group and the sham taVNS group). Subjects received one session of taVNS (active or sham) for 60 min. QEEG was recorded before and after the interventions, and the subjects were assessed while exposed to emotional conditions with sad and happy facial expressions, followed by a Go/No-Go trial. The results demonstrated a significant increase in N2 amplitude in the No-Go condition for the active taVNS post-intervention compared to the sham taVNS after adjusting by handedness, mood, and fatigue levels (p = 0.046), significantly reduced ERD during sad conditions after treatment (p = 0.037), and increased frontal alpha asymmetry towards the right frontal hemisphere during the emotional task condition (p = 0.046). Finally, we observed an interesting neural signature in this study that suggests a bottom-up modulation from brainstem/subcortical to cortical areas as characterized by improved lateralization of alpha oscillations towards the frontal right hemisphere, and changes in ERP during emotional and Go/No-Go tasks that suggests a better subcortical response to the tasks. Such bottom-up effects may mediate some of the clinical effects of taVNS., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
49. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
- Author
-
Ferreiro-Iglesias R, Porto Silva S, Marín S, Casanova MJ, Mañosa M, González-Muñoza C, de Francisco R, Caballol B, Arias L, Piqueras M, Zabana Y, Rivero M, Calvet X, Mesonero F, Varela Trastoy P, Busta Nistal R, Gómez Perosanz R, Vega P, Gonzalez-Vivo M, Iborra M, Bermejo F, Madero L, Rodríguez-Lago I, Rodríguez Gonzalez M, Vera I, Ponferrada Díaz Á, Vela M, Torrealba Medina L, Van Domselaar M, Gomollón F, Iglesias E, Gisbert JP, Calafat M, Giordano A, Pérez-Martínez I, Ricart E, Sicilia B, Mena R, Esteve M, Rivas C, Brunet-Mas E, Fernández C, de Jorge Turrión MÁ, Velayos Jiménez B, Quiñones Calvo M, Regueiro Expósito C, Márquez-Mosquera L, Nos P, Granja A, Gutiérrez A, Cabriada JL, Hervías Cruz D, Calvo M, Pérez Pérez J, Rodríguez Díaz Y, Busquets Casal D, Menacho M, Leal C, Lucendo AJ, Royo V, Olivares S, Álvarez Herrero B, Carrillo-Palau M, Gilabert Álvarez P, Manceñido Marcos N, Martínez-Pérez TJ, Muñoz Villafranca MC, Almela P, Argüelles-Arias F, Legido J, Fuentes Coronel AM, Nieto L, Domènech E, and Barreiro-de Acosta M
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Prospective Studies, Registries, Proctitis drug therapy, Colitis, Ulcerative drug therapy, Immunosuppressive Agents therapeutic use
- Abstract
Background: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence, however, is scarce because these patients are excluded from randomised controlled clinical trials. Our aim was to describe the characteristics of patients with refractory UP and their disease-related complications, and to identify the need for immunosuppressive therapies., Methods: We identified patients with UP from the prospective ENEIDA registry sponsored by the GETECCU. We evaluated socio-demographic data and complications associated with immunosuppression. We defined immunosuppression as the use of immunomodulators, biologics and/or small molecules. We used logistic regression to identify factors associated with immunosuppressive therapy., Results: From a total of 34,716 patients with ulcerative colitis, we identified 6281 (18.1%) with UP; mean ± SD age 53 ± 15 years, average disease duration of 12 ± 9 years. Immunosuppression was prescribed in 11% of patients, 4.2% needed one biologic agent and 1% needed two; 2% of patients required hospitalisation, and 0.5% underwent panproctocolectomy or subtotal colectomy. We identified 0.2% colorectal tumours and 5% extracolonic tumours. Patients with polyarthritis (OR 3.56, 95% CI 1.86-6.69; p < 0.001) required immunosuppressants., Conclusions: Among patients with refractory UP, 11% required immunosuppressant therapy, and 4.2% required at least one biologic agent., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
50. Transcutaneous vagus nerve stimulation effects on chronic pain: systematic review and meta-analysis.
- Author
-
Costa V, Gianlorenço AC, Andrade MF, Camargo L, Menacho M, Arias Avila M, Pacheco-Barrios K, Choi H, Song JJ, and Fregni F
- Abstract
Chronic pain is one of the major causes of disability with a tremendous impact on an individual's quality of life and on public health. Transcutaneous vagus nerve stimulation (tVNS) is a safe therapeutic for this condition. We aimed to evaluate its effects in adults with chronic pain. A comprehensive search was performed, including randomized controlled trials published until October 2023, which assessed the effects of noninvasive tVNS. Cohen's d effect size and 95% confidence intervals (CIs) were calculated, and random-effects meta-analyses were performed. Fifteen studies were included. The results revealed a mean effect size of 0.41 (95% CI 0.17-0.66) in favor of tVNS as compared with control, although a significant heterogeneity was observed (χ
2 = 21.7, df = 10, P = 0.02, I2 = 53.9%). However, when compared with nonactive controls, tVNS shows a larger effect size (0.79, 95% CI 0.25-1.33), although the number of studies was small (n = 3). When analyzed separately, auricular tVNS and cervical tVNS against control, it shows a significant small to moderate effect size, similar to that of the main analysis, respectively, 0.42 (95% CI 0.08-0.76, 8 studies) and 0.36 (95% CI 0.01-0.70, 3 studies). No differences were observed in the number of migraine days for the trials on migraine. This meta-analysis indicates that tVNS shows promise as an effective intervention for managing pain intensity in chronic pain conditions. We discuss the design of future trials to confirm these preliminary results, including sample size and parameters of stimulation., Competing Interests: H. Choi and J.-J. Song are directly associated with Neurive Co, a company developing neuromodulation technologies, such as taVNS, to treat common brain diseases. F. Fregni is supported by NIH grants and by a research grant and gift from Neurive to Spaulding Rehabilitation Hospital. Fregni is also a consultant for Neurive. The remaining authors have no conflicts of interest to declare., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.